Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis

Journal of Surgical Oncology

Volumn 102, Issue 7, 2010, Pages 748-752

  Arigami, Takaaki ^a   Uenosono, Yoshikazu ^a   Hirata, Munetsugu ^a   Hagihara, Takahiko ^a   Yanagita, Shigehiro ^a   Ishigami, Sumiya ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

B7 H4; gastric cancer; prognosis; reverse transcription polymerase chain reaction; tumor progression

Indexed keywords

B7 ANTIGEN; MESSENGER RNA; PROTEIN B 7 H 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; STOMACH CANCER; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD80; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GASTRECTOMY; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 78649661358     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21722     Document Type: Article

References (37)

1. Hirata K, Horikoshi N, Aiba K, et al.: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 1999; 5: 2000-2005.
2. Ohtsu A:, Current status and future prospects of chemotherapy for metastatic gastric cancer: A review. Gastric Cancer 2005; 8: 95-102.
3. Ajani JA, Faust J, Ikeda K, et al.: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005; 23: 6957-6965.
4. Ohtsu A, Yoshida S, Saijo N:, Disparities in gastric cancer chemotherapy between the east and west. J Clin Oncol 2006; 24: 2188-2196.
5. Koizumi W, Narahara H, Hara T, et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008; 9: 215-221.
6. Statistics and Information Department, Ministry of Health, Labour, and Welfare. Vital Statistics of Japan 2004. Tokyo: Health and Welfare Statistics Association; 2006.
7. Kwon SJ, Kim GS:, Prognostic significance of lymph node metastasis in advanced carcinoma of the stomach. Br J Surg 1996; 83: 1600-1603.
8. Nitti D, Marchet A, Olivieri M, et al.: Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: Analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003; 10: 1077-1085.
9. Kunisaki C, Makino H, Takagawa R, et al.: Tumor diameter as a prognostic factor in patients with gastric cancer. Ann Surg Oncol 2008; 15: 1959-1967.
10. Xi WD, Zhao C, Ren GS:, Endoscopic ultrasonography in preoperative staging of gastric cancer: Determination of tumor invasion depth, nodal involvement and surgical respectability. World J Gastroenterol 2003; 9: 254-257.
11. Flies DB, Chen L:, Modulation of immune response by B7 family molecules in tumor microenvironments. Immunol Invest 2006; 35: 395-418.
12. Flies DB, Chen L:, The new B7s: Playing a pivotal role in tumor immunity. J Immunother 2007; 30: 251-260.
13. Zang X, Allison JP:, The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res 2007; 13: 5271-5279.
14. Prasad DV, Richards S, Mai XM, et al.: B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003; 18: 863-873.
15. Sica GL, Choi IH, Zhu G, et al.: B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003; 18: 849-861.
16. Zang X, Loke P, Kim J, et al.: B7x: A widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci 2003; 100: 10388-10392.
17. Ichikawa M, Chen L:, Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: Novel cancer escaping mechanisms. Front Biosci 2005; 10: 2856-2860.
18. Sadun RE, Sachsman SM, Chen X, et al.: Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res 2007; 13: 4016-4025.
19. Tringler B, Zhuo S, Pilkington G, et al.: B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 2005; 11: 1842-1848.
20. Simon I, Zhuo S, Corral L, et al.: B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006; 66: 1570-1575.
21. Sun Y, Wang Y, Zhao J, et al.: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006; 53: 143-151.
22. Krambeck AE, Thompson RH, Dong H, et al.: B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proc Natl Acad Sci USA 2006; 103: 10391-10396.
23. Simon I, Katsaros D, Rigault de la Longrais I, et al.: B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol 2007; 106: 334-341.
24. Kryczek I, Wei S, Zhu G, et al.: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67: 8900-8905.
25. Zheng Y, Katsaros D, Shan SJ, et al.: A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res 2007; 13: 6984-6992.
26. Awadallah NS, Shroyer KR, Langer DA, et al.: Detection of B7-H4 and p53 in pancreatic cancer: Potential role as a cytological diagnostic adjunct. Pancreas 2008; 36: 200-206.
27. Miyazono F, Natsugoe S, Takao S, et al.: Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. Ann Surg 2001; 233: 189-194.
28. Ishigami S, Sakamoto A, Uenosono Y, et al.: Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer. J Surg Res 2008; 148: 205-209.
29. Arigami T, Natsugoe S, Uenosono Y, et al.: Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer 2005; 93: 688-693.
30. Arigami T, Natsugoe S, Uenosono Y, et al.: Evaluation of sentinel node concept in gastric cancer based on lymph node micrometastasis determined by reverse transcription-polymerase chain reaction. Ann Surg 2006; 243: 341-347.
31. Sobin LH, Wittenkind CH:, International union against cancer. TNM classification of malignant tumors, 6th edition. New York: John Wiley-Liss; 2002.
32. Isomoto H, Shikuwa S, Yamaguchi N, et al.: Endoscopic submucosal dissection for early gastric cancer: A large-scale feasibility study. Gut 2009; 58: 331-336.
33. Jee YS, Hwang SH, Rao J, et al.: Safety of extended endoscopic mucosal resection and endoscopic submucosal dissection following the Japanese Gastric Cancer Association treatment guidelines. Br J Surg 2009; 96: 1157-1161.
34. Hodi FS, Mihm MC, Soiffer RJ, et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 4712-4717.
35. Sanderson K, Scotland R, Lee P, et al.: Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 741-750.
36. Beck KE, Blansfield JA, Tran KQ, et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289.
37. O'Mahony D, Morris JC, Quinn C, et al.: A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007; 13: 958-964.